EU Risk Management Plan

for

Fesoterodine Accord 4 mg Prolonged-Release Tablets

Fesoterodine Accord 8 mg Prolonged-Release Tablets

(Fesoterodine Fumarate)

RMP version to be assessed as part of this application:

RMP Version number	2.1
Data lock point for this RMP	27-May-2022
Date of final sign off	28-May-2022

Rationale for submitting an updated RMP: RMP has been updated as per - Czech Republic (CZ) Comments Day 145 and as per latest approved RMP of reference medicinal product Toviaz (version number 10.0, date of final sign off 19-Mar-2021).

Summary of significant changes in this RMP: Significant changes have been done in followings sections of RMP: Part II (Module SVII and Module SVIII), Part VI and Part VII (Annexure 7 and Annexure 8)

Other RMP versions under evaluation: Not applicable

Details of the currently approved RMP:

Version number	Approved with procedure	Date of approval (opinion date)
Version 1.1	NL/H/5107/001/DC	07-May-2021

QPPV name: Agata Gesiewicz

QPPV signature: Agata Gesiewicz

TABLE OF CONTENTS

LIST OF TABLES

Part I: Product(s) Overview

Table 1: Product Overview

Active substance(s) (INN or common name)	Fesoterodine fumarate
Pharmacotherapeutic group(s)(ATC Code)	Pharmacotherapeutic group: Urologicals, Urinary antispasmodics ATC code: G04BD11
Marketing Authorisation Holder/ Applicant	Accord Healthcare B.V., Netherlands
Medicinal products to which this RMP refers	2
Invented name(s) in the European Economic Area (EEA)	Fesoterodine Accord 4 mg Prolonged-Release Tablets Fesoterodine Accord 8 mg Prolonged-Release Tablets
Marketing authorisation procedure	Decentralised Procedure (NL/H/5107/001/DC and NL/H/5107/002/DC)
Brief description of the product	Chemical Class: A competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties.
	Summary of mode of action: Fesoterodine is a competitive, specific muscarinic receptor antagonist. It is rapidly and extensively hydrolysed by non-specific plasma esterases to the 5-hydroxymethyl derivative, its primary active metabolite, which is the main active pharmacological principle of fesoterodine.
	Important information about its composition:

	Fesoterodine 4 mg tablets Each prolonged-release tablet contains 4 mg fesoterodine fumarate corresponding to 3.1 mg of fesoterodine. *Fesoterodine 8 mg tablets* Each prolonged-release tablet contains fesoterodine fumarate 8 mg corresponding to 6.2 mg of fesoterodine Excipient(s) with known effect: *Fesoterodine 4 mg tablets* Each 4 mg prolonged-release tablet contains 0.3 mg of soya lecithin and 70 mg of lactose. *Fesoterodine 8 mg tablets* Each 8 mg prolonged-release tablet contains 0.3 mg of soya lecithin and 70 mg of lactose. **List of excipients:** *Fesoterodine 4 mg tablets* Tablet core Cellulose microcrystalline (E460) Hypromellose (E464) Lactose anhydrous Silicon dioxide (E551) Magnesium stearate (E572) Film-coating Titanium dioxide (E171) Talc (E553b) Soya lecithin (E322) Xanthan gum (E415) Iron oxide yellow (E172)

	Fesoterodine 8 mg tablets: Tablet core Cellulose microcrystalline (E460) Hypromellose (E464) Lactose anhydrous Silicon dioxide (E551) Magnesium stearate (E572) Film-coating Titanium dioxide (E171) Talc (E553b) Soya lecithin (E322) Xanthan gum (E415) Indigo carmine aluminium lake (E132)
Hyperlink to the Product Information	Refer Module 1.3.1 for Product Information
Indication(s) in the EEA Current and Proposed	Fesoterodine fumarate Accord tablets is indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.
Dosage in the EEA Proposed	**Posology** Adults (including elderly) The recommended starting dose is 4 mg once daily. Other products are available for the recommended starting dose of 4 mg. Based upon individual response, the dose may be increased to 8 mg once daily. The maximum daily dose is 8 mg. Full treatment effect was observed between 2 and 8 weeks. Hence, it is recommended to re-evaluate the efficacy for the individual patient after 8 weeks of treatment.

	In subjects with normal renal and hepatic function receiving concomitant administration of potent CYP3A4 inhibitors, the maximum daily dose of fesoterodine fumarate should be 4 mg once daily. **<u>Method of administration</u>** Tablets are to be taken once daily with liquid and swallowed whole. Fesoterodine fumarate can be administered with or without food.
Pharmaceutical form(s) and strengths	Current: Prolonged-release Tablets 8 mg
	Proposed: Prolonged-release Tablets 4 mg
Is the product be subject to additional monitoring in the EU?	No

Part II: Safety specification

Module SI – Epidemiology of the indication(s) and target population(s)

Not applicable

Module SII – Non-clinical part of the safety specification

Not applicable

Module SIII – Clinical trial exposure

Not applicable

Module SIV – Populations not studied in clinical trials

SIV.1 Exclusion criteria in pivotal clinical studies within the development programme

Not applicable

SIV.2 Limitations to detect adverse reactions in clinical trial development programmes

Not applicable

SIV.3 Limitations in respect to populations typically under-represented in clinical trial development programmes

Not applicable

Module SV – Post-authorisation experience

SV.1 Post-authorisation exposure

Not applicable

Module SVI – Additional EU requirements for the safety specification

Potential for misuse for illegal purposes

Not applicable

Module SVII – Identified and potential risks

The safety concerns for this RMP have been updated as per latest approved RMP of reference medicinal product Toviaz (version number 10.0, date of final sign off 19 March 2021) as suggested in CZ Comments Day 145 of Fesoterodine Accord. These safety concerns are list in Module SVIII of this RMP. MAH does not propose any update.

SVII.1 Identification of safety concerns in the initial RMP submission

SVII.1.1Risks not considered important for inclusion in the list of safety concerns in the RMP

Not applicable

SVII.1.2 Risks considered important for inclusion in the list of safety concerns in the RMP

Not applicable

SVII.2 New safety concerns and reclassification with a submission of an updated RMP

Not applicable

SVII.3 Details of important identified risks, important potential risks, and missing information

SVII.3.1 Presentation of important identified risks and important potential risks

Not applicable

SVII.3.2. Presentation of the missing information

Not applicable

Module SVIII – Summary of the safety concerns

Table 2: Summary of safety concerns

Important identified risks	• None
Important potential risks	• None
Missing information	• None

Part III: Pharmacovigilance Plan (including post-authorisation safety studies)

III.1 Routine pharmacovigilance activities

Routine pharmacovigilance activities including collection and reporting of adverse reactions and signal detection as stated in pharmacovigilance system master file are considered sufficient .

III.2 Additional pharmacovigilance activities

None proposed

III.3 Summary Table of additional Pharmacovigilance activities

Not applicable

Part IV: Plans for post-authorisation efficacy studies

Not applicable

Part V: Risk minimisation measures (including evaluation of the effectiveness of risk minimisation activities)

The safety information in the proposed product information is aligned to the reference medicinal product.

V.1 Routine Risk Minimisation Measures

Not applicable

V.2 Additional Risk Minimisation Measures

None proposed

V.3 Summary of risk minimisation measures

Not applicable

Part VI: Summary of the risk management plan

Summary of risk management plan for Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets (Fesoterodine Fumarate)

This is a summary of the risk management plan (RMP) for Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets. The RMP details important risks of Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets, how these risks can be minimised, and how more information will be obtained about Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets' risks and uncertainties (missing information).

Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets' summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets should be used.

Important new concerns or changes to the current ones will be included in updates of Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets's RMP.

I. The medicine and what it is used for

Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets is indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.

It contains fesoterodine fumarate as the active substance and it is given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets together with measures to minimise such risks and the proposed studies for learning more about Fesoterodine Accord 8 mg Prolonged-Release Tablets' risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment and signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of 'Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets' is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Fesoterodine Accord 4 mg and 8 mg prolonged-release tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets.

Part VII: Annexes

Annex 1 – EudraVigilance Interface

Not applicable.

Annex 2 – Tabulated summary of planned, ongoing, and completed pharmacovigilance study programme

Not applicable

Annex 3 – Protocols for proposed, on-going and completed studies in the pharmacovigilance plan

Not applicable

Annex 4 – Specific adverse drug reaction follow-up forms

Not applicable

Annex 5 – Protocols for proposed and on-going studies in RMP part IV

Not applicable

Annex 6 – Details of proposed additional risk minimisation activities

Not applicable

Annex 7 – Other supporting data (including referenced material)

1. Summary of Product Characteristics of Fesoterodine Accord 4 mg and 8 mg Prolonged-Release Tablets.
2. CZ Comments Day 145 of Fesoterodine Accord and latest approved RMP of reference medicinal product Toviaz (version number 10.0, date of final sign off 19-Mar-2021).

Annex 8 – Summary of changes to the risk management plan over time

Version	**Approval date** **Procedure**	**Change**
1.1	07-May-2021	Summary of changes in RMP version 2.0: RMP has been updated to file Line extention application (NL/H/5107/002/DC). Administrative details have been updated.
2.1	Not applicable NL/H/5107/001/DC and NL/H/5107/002/DC	Summary of changes in RMP version 2.1: • RMP has been updated as per - CZ Comments Day 145 and as per latest approved RMP of reference medicinal product Toviaz (version number 10.0, date of final sign off 19-Mar-2021). • All safety concerns have been removed from RMP as suggested in Day 145 Comments